BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 21482977)

  • 1. Active and passive immunotherapy for lymphoma: proving principles and improving results.
    Brody J; Kohrt H; Marabelle A; Levy R
    J Clin Oncol; 2011 May; 29(14):1864-75. PubMed ID: 21482977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy.
    Baxevanis CN; Perez SA; Papamichail M
    Cancer Immunol Immunother; 2009 Mar; 58(3):317-24. PubMed ID: 18704409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
    Bodey B; Siegel SE; Kaiser HE
    Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
    Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
    Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade.
    Weber J
    Semin Oncol; 2010 Oct; 37(5):430-9. PubMed ID: 21074057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Active vaccination after allogeneic bone marrow cell transplantation: a new option in the immunotherapy of cancer?
    Zöller M; Matzku S
    Arch Immunol Ther Exp (Warsz); 2002; 50(3):197-224. PubMed ID: 12098935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy in mantle cell lymphoma: anti-CD20-based therapy and beyond.
    Zhou Y; Zhang L; Romaguera J; Delasalle K; Han X; Du X; Kwak L; Yi Q; Wang M
    Am J Hematol; 2008 Feb; 83(2):144-9. PubMed ID: 17722077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate cancer immunotherapy.
    McNeel DG
    Curr Opin Urol; 2007 May; 17(3):175-81. PubMed ID: 17414515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New antibody approaches to lymphoma therapy.
    Suresh T; Lee LX; Joshi J; Barta SK
    J Hematol Oncol; 2014 Sep; 7():58. PubMed ID: 25355407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunomodulation against leukemias and lymphomas: a realistic future treatment?
    Mittal S; Marshall NA; Barker RN; Vickers MA
    Crit Rev Oncol Hematol; 2008 Feb; 65(2):101-8. PubMed ID: 17719232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Immunotherapy for cancer--modern immunologic strategies in oncology].
    Halama N; Zoernig I; Jäger D
    Dtsch Med Wochenschr; 2008 Oct; 133(41):2105-8. PubMed ID: 18985564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
    Khawli LA; Hu P; Epstein AL
    Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in specific immunotherapy for prostate cancer.
    Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
    Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic lymphoma vaccines: importance of T-cell immunity.
    Neelapu SS; Lee ST; Qin H; Cha SC; Woo AF; Kwak LW
    Expert Rev Vaccines; 2006 Jun; 5(3):381-94. PubMed ID: 16827622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
    Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
    Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccines for lymphomas: idiotype vaccines and beyond.
    Houot R; Levy R
    Blood Rev; 2009 May; 23(3):137-42. PubMed ID: 18951668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Personalized immunotherapy for the treatment of non-Hodgkin's lymphoma: a promising approach.
    Vose JM
    Hematol Oncol; 2006 Jun; 24(2):47-55. PubMed ID: 16447298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer immunotherapy.
    Schuster M; Nechansky A; Kircheis R
    Biotechnol J; 2006 Feb; 1(2):138-47. PubMed ID: 16892244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-idiotypic therapy of leukemias and lymphomas.
    Stevenson FK; George AJ; Glennie MJ
    Chem Immunol; 1990; 48():126-66. PubMed ID: 2403803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of central nervous system lymphomas using monoclonal antibodies: challenges and opportunities.
    Wong ET
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7151s-7157s. PubMed ID: 16203815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.